For Natera's Prospera transplant assessment test, should we invest in improving sensitivity or expanding organ compatibility beyond kidneys?

Introduction

The trade-off we're examining today is whether to invest in improving sensitivity or expanding organ compatibility beyond kidneys for Natera's Prospera transplant assessment test. This decision is crucial for Natera's product strategy and market positioning in the transplant diagnostics space. I'll analyze this trade-off by considering the product's current state, potential impacts, key metrics, and experimental approaches to guide our decision-making process.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking Prospera is currently focused on kidney transplants. Could you confirm if there are any other organs we're already assessing, and what's driving the consideration for expansion?

Why it matters: Helps understand current product scope and market demand Expected answer: Primarily kidney, with increasing interest in other organs Impact on approach: Would influence prioritization of expansion vs. improvement

• Business Context: Based on our market position, I assume improving sensitivity could increase our competitive edge. How does our current sensitivity compare to competitors, and what's the revenue impact of even a small improvement?

Why it matters: Assesses potential ROI of sensitivity improvement Expected answer: We're competitive but not leading; small improvements have significant revenue impact Impact on approach: Would justify investment in sensitivity if the revenue impact is substantial

• User Impact: I'm thinking about transplant centers as our primary users. How would expanding to other organs affect their workflow and adoption of our test?

Why it matters: Evaluates potential user friction or benefits from expansion Expected answer: Minimal workflow changes, potential for increased test orders Impact on approach: Would favor expansion if it aligns well with user needs and behaviors

• Technical Feasibility: Considering our current platform, I'm curious about the technical challenges in improving sensitivity versus expanding to other organs. Which option presents more significant technical hurdles?

Why it matters: Assesses feasibility and resource requirements for each option Expected answer: Sensitivity improvement more challenging but leverages existing expertise Impact on approach: Would influence resource allocation and timeline estimates

• Resource and Timeline: Given our current team structure, I'm wondering about the resource requirements and timeline for each option. Can you give me an idea of the team capacity and budget constraints we're working with?

Why it matters: Helps prioritize options based on available resources and urgency Expected answer: Limited resources, preference for quicker wins Impact on approach: Would favor the option that aligns better with current resources and delivers faster results